Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer

Clinical guidelines promote the identification of several targetable biomarkers to drive treatment decisions in advanced non-small cell lung cancer (NSCLC), but half of all patients do not have a viable biopsy. Specimens from endobronchial-ultrasound transbronchial needle aspiration (EBUS-TBNA) are an alternative source of material for the initial diagnosis of NSCLC, however their usefulness for a complete molecular characterization remains controversial. EBUS-TBNA samples were prospectively tested for several biomarkers by next-generation sequencing (NGS), nCounter, and immunohistochemistry (PD-L1). The primary objectives were to assess the sensitivity of EBUS-TBNA samples for a comprehensive molecular characterization and to compare its performance to the reference standard of biopsy samples. Seventy-two EBUS-TBNA procedures were performed, and 42 NSCLC patients were diagnosed. Among all cytological samples, 92.9% were successfully genotyped by NGS, 95.2% by nCounter, and 100% by immunohistochemistry. There were 29 paired biopsy samples; 79.3% samples had enough tumor material for genomic genotyping, and 96.6% for PD-L1 immunohistochemistry. A good concordance was found between both sources of material: 88.9% for PD-L1, 100% for NGS and nCounter. EBUS-TBNA is a feasible alternative source of material for NSCLC genotyping and allows the identification of patient candidates for personalized therapies with high concordance when compared with biopsy.

Download Full-text

Bevacizumab in Non-small Cell Lung Cancer: An Overview of Practice in the Era of Molecular Testing

Clinical Oncology ◽

10.1016/j.clon.2014.05.004 ◽

2014 ◽

Vol 26 (8) ◽

pp. 468-472 ◽

Cited By ~ 3

Author(s):

M. Snee

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Molecular Testing ◽

Small Cell Lung

Download Full-text

Multiplex digital colour-coded barcode technology on RNA extracted from routine cytological samples of patients with non-small cell lung cancer: pilot study

Journal of Clinical Pathology ◽

10.1136/jclinpath-2017-204373 ◽

2017 ◽

Vol 70 (9) ◽

pp. 803-806 ◽

Cited By ~ 7

Author(s):

Roberta Sgariglia ◽

Pasquale Pisapia ◽

Mariantonia Nacchio ◽

Caterina De Luca ◽

Francesco Pepe ◽

...

Keyword(s):

Lung Cancer ◽

Pilot Study ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Secondary Analysis ◽

Small Cell ◽

Parameter Analysis ◽

Molecular Testing ◽

Small Cell Lung ◽

Advanced Stages

In the advanced stages of non-small cell lung cancer (NSCLC), molecular testing is often performed on archival cytological smears. The nCounter system (NanoString Technologies) is a new promising multiplex digital colour-coded barcode technology. However, its feasibility to evaluate the RNA expression of clinical relevant biomarkers on routine cytological smears is still uncertain. To this end, RNA was extracted from 12 NSCLC routine stained cytological smears, and nCounter analysis performed by using a 48-gene panel. Overall, 11/12 (92%) of the smears were adequate for the secondary analysis, fulfilling the quality check parameter analysis of nSolver software. This pilot study shows that RNA nCounter analysis is feasible on routine cytological smears preparing the field for the implementation of this technology in the routine setting.

Download Full-text

Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non‐Small Cell Lung Cancer

The Oncologist ◽

10.1634/theoncologist.2017-0042 ◽

2017 ◽

Vol 22 (11) ◽

pp. 1325-1332 ◽

Cited By ~ 1

Author(s):

Yanxi Han ◽

Rui Zhang ◽

Guigao Lin ◽

Kuo Zhang ◽

Jiehong Xie ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Quality Assessment ◽

Molecular Diagnosis ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung

Download Full-text

Integration of a nurse navigator into the triage process for patients with non-small-cell lung cancer: creating systematic improvements in patient care

Current Oncology ◽

10.3747/co.23.2954 ◽

2016 ◽

Vol 23 (3) ◽

pp. 280 ◽

Cited By ~ 5

Author(s):

K. Zibrik ◽

J. Laskin ◽

C. Ho

Keyword(s):

Lung Cancer ◽

New York ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Systemic Treatment ◽

Small Cell ◽

Molecular Testing ◽

Small Cell Lung ◽

Number Of Patients ◽

Nurse Navigator

Nurse navigation is a developing facet of oncology care. The concept of patient navigation was originally created in 1990 at the Harlem Hospital Center in New York City as a strategy to assist vulnerable and socially disadvantaged populations with timely access to breast cancer care. Since the mid-1990s, navigation programs have expanded to include many patient populations that require specialized management and prompt access to diagnostic and clinical resources. Advanced non-small-cell lung cancer is ideally suited for navigation to facilitate efficient assessment in this fragile patient population and to ensure timely results of molecular tests for first-line therapy with appropriately targeted agents. At the BC Cancer Agency, nurse navigator involvement with thoracic oncology triage has been demonstrated to increase the proportion of patients receiving systemic treatment, to shorten the time to delivery of systemic treatment, and to increase the rate of molecular testing and the number of patients with molecular testing results available at time of initial consultation. Insights gained through the start-up process are briefly discussed, and a framework for implementation at other institutions is outlined.

Download Full-text

The targetable mutation landscape of Chinese patients with non-small cell lung cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.e13018 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. e13018-e13018

Author(s):

Jun Li ◽

Cuiyun Zhang ◽

Jiuzhou Zhao ◽

Zhizhong Wang ◽

Bing Wei ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitors ◽

Small Cell ◽

Chinese Patients ◽

Molecular Testing ◽

Small Cell Lung ◽

Essential Information ◽

Nsclc Patients

e13018 Background: In recent years, the prognosis of non-small cell lung cancer (NSCLC) patients has been substantially improved by targeted therapies against specific molecular aberrations, i.e. tyrosine kinase inhibitors (TKIs) for Epidermal Growth Factor Receptor ( EGFR) etc. Several genes have been suggested by NCCN guideline (v7.2017) to test for NSCLC patients, including EGFR, ALK, ROS1, BRAF, MET, RET, HER2 and KRAS. The aim of this study is to profile the landscape of actionable mutations in Chinese NSCLC patients. Methods: From 2015 to 2017 621 treatment naïve NSCLC patients enrolled in the affiliated cancer hospital of Zhengzhou University were included in this analysis. DNA was extracted from the FFPE biopsies of these patients and processed for target capture sequencing covering the exons and flanking splicing regions of the 8 genes suggested by NCCN guideline, as well as introns of ROS, ALK and RET. Results: In total, 593 out of the 621 NSCLC patients harbor one or more mutations in these 8 genes, accounting for 95.5% of all the cases. EGFR, ALK and HER2 are the top 3 mutants, with a frequency of 52%, 32% and 26% respectively. Genetic aberrations in BRAF, MET, ROS1, KRAS and RET occur in 22%, 18%, 16% and 14% of the patients. The most common variation is missense; T > G, C > T and C > A changes are more often observed than T > C, T > A and C > G; the median number of variants per sample is 2, ranging from 1 to 13. There are 418 mutations detected on EGFR, of which 206 (49.28%) are clinically relevant. EGFR L858R, Exon19 deletion, Exon20 insertion, G719, A750P were observed in 123 (29.43%), 43 (10.29%), 8 (1.91%), 6 (1.44%) and 6 (1.44%) cases respectively. Gene fusions were identified in 78 cases, and the EML4- ALK is the most common one occurred in 54 patients, other fusion genes include KIF5B- ALK (11) ， CCDC6- RET (4), CD74- ROS1 (4), EZR- ROS1 (2), ERC1- RET (1), , SDC4- ROS1 (1) and TCOF1- ROS1 (1). Conclusions: Target sequencing of the 8 genes suggested by NCCN guideline for NSCLC patients reveals essential information for designing personalized therapeutic regimen. Chinese patients, maybe other Asian countries also, may benefit more from this molecular testing, because of the high occurrence of actionable mutations.

Download Full-text